Global Cell and Gene Therapy Market to Expand at USD 190.82 Billion by 2033
According to Straits Research, the global cell and gene therapy market size was valued at $30.27 billion in 2024. It is projected to reach $37.14 billion in 2025 and further expand to $190.82 billion by 2033, growing at a CAGR of 22.7% during the forecast period (2025–2033).
Market Overview
The cell and gene therapy market is witnessing a significant surge, driven by advancements in biotechnology, personalized medicine, and innovative treatment approaches for various chronic and genetic disorders. Cell therapy focuses on replacing or repairing damaged tissues and cells, while gene therapy aims to treat diseases by modifying genetic material. The market is seeing increased investments from pharmaceutical companies and research institutions, driving growth in both developed and emerging economies.
Market Trends
Rising Approvals and Research Funding: Regulatory approvals for gene therapy treatments are accelerating, with government and private funding boosting clinical trials and research initiatives.
Advancements in CAR-T Cell Therapy: CAR-T therapy is becoming a prominent treatment option for certain cancers, with ongoing research aimed at improving efficacy and safety.
Growing Demand for Personalized Medicine: The shift toward individualized treatment approaches is fostering the development of innovative gene-editing technologies.
Expansion of Manufacturing Capabilities: Companies are investing in advanced production facilities to meet the growing demand for cell and gene therapies globally.
Key Opportunity
The market presents a lucrative opportunity for stakeholders, particularly in oncology, rare diseases, and regenerative medicine. Strategic collaborations, mergers, and acquisitions among biotech firms and pharmaceutical giants are expected to accelerate market expansion.
Download Free Sample Report with Complimentary Analyst Consultation : https://straitsresearch.com/report/cell-and-gene-therapy-market/request-sample
Leading Companies in the Cell and Gene Therapy Market
1. Thermo Fisher Scientific
2. Merck KGaA
3. Charles River Laboratories
4. Lonza
5. Catalent
6. WuXi AppTec
7. Takara Bio Inc.
8. Nikon Corporation
9. FUJIFILM Holdings Corporation
10. Hoffmann-La Roche Ltd.
11. Oxford Biomedica plc
12. Amgen Inc.
13. Novartis AG
14. Pfizer Inc.
15. Biogen Inc.
Market Segmentation
By Therapy Type
1. Cell Therapy
CAR-T
Autologous CAR-T
Allogeneic CAR-T
CAR-NK
B-Cell
Other
Gene Therapy
Viral
AAV
Lentiviral vectors
Other
Non-Viral
By Indication
2. Oncology Diseases
3. Cardiovascular Diseases
4. Orthopedic Diseases
5. Ophthalmology Diseases
6. Central Nervous System Disorders
7. Infectious Diseases
8. Others
By Delivery Method
9. In Vivo
10. Ex Vivo
By End User
11. Pharmaceutical Biotechnology Companies
12. Academic Research Institutes
13. Others
By Application
14. Oncology
15. Dermatology
16. Musculoskeletal
17. Others
Conclusion
The cell and gene therapy market is poised for unprecedented growth, fueled by scientific breakthroughs and increasing patient demand for advanced treatments. As companies continue to develop and commercialize novel therapies, the industry is set to transform the healthcare landscape, offering new hope for patients worldwide.
About Straits Research
Straits Research is a leading provider of business intelligence, specializing in research, analytics, and advisory services, with a focus on delivering in-depth insights through comprehensive reports.
Contact Us:
Email: sales@straitsresearch.com
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)
Address: 825 3rd Avenue, New York, NY, USA, 10022
